SLC7A11 and neoplasm: Similarly, targeting SLC7A11 (xCT) with sulfasalazine or siRNA-loaded nanoparticles inhibited tumor progression and remodeled the tumor microenvironment by limiting cystine uptake and redox buffering [59].